Ariceum Therapeutics is a privately held radiopharmaceutical firm in the clinical stage that specializes in the detection and targeted treatment of aggressive malignancies, such as neuroendocrine and other hard-to-treat cancers.177Lu-satoreotide tetraxetan (Satoreotide), the company's primary targeted systemic radiopharmaceutical therapy, isan antagonist of the somatostatin type 2 receptor (SSTR2), which is overexpressed in many neuroendocrine tumors. For the simultaneous diagnosis and targeted radionuclide treatment of neuroendocrine malignancies, some aggressive tumors, and childhood cancer, which currently offers few treatment choices and a poor prognosis, we are developing satoreotide as a "theranostic" pair.

Biotechnology

Health Care

Therapeutics

Ariceum Therapeutics

Ariceum Therapeutics' headquarters in Berlin, Germany

Manfred Ruediger

Erwin Bachmohr

Brigitta Voss

Aaron Block, MBA

Serge SAGODIRA

Germo Gericke

Dennis MEWIS

Anika Jäkel

Description

People (5)

Dennis MEWIS

Manuel Sturzbecher-Hoehne

Anamaria Pop

Prachi Desai

Liam Rayman

Jobs